SLFN5 and renal cell carcinoma: However, SLFN5 also potentially reduces the anticancer effect of IFN in glioma cancer cells by transcriptionally co-repressing STAT1-mediated IFN responses, in contrast to its beneficial role in melanoma and renal cell carcinoma [65].